99% Bulk Neratinib CAS 698387-09-6 Anti Breast Cancer Neratinib Powder
China 99% Bulk Neratinib CAS 698387-09-6 Anti Breast Cancer Neratinib Powder, Find details about China Neratinib, Neratinib Use from 99% Bulk Neratinib CAS 698387-09-6 Anti Breast Cancer Neratinib Powder
Basic Info.
Model NO.
hupharma
Payment
Bitcoin/Wu/Mg/Wire Transfer
Minimum
10g
Delivery Time
1-3 Days
Shipping
Worldwide
Trademark
hupharma
Transport Package
Safe and Fast Delivery
Specification
10g, 100g, 1kg
Origin
China
HS Code
2937290090
Model NO.
hupharma
Payment
Bitcoin/Wu/Mg/Wire Transfer
Minimum
10g
Delivery Time
1-3 Days
Shipping
Worldwide
Trademark
hupharma
Transport Package
Safe and Fast Delivery
Specification
10g, 100g, 1kg
Origin
China
HS Code
2937290090
Product Desciption
99% Bulk Neratinib CAS 698387-09-6 Anti Breast Cancer Neratinib Powder
Product Name: Neratinib
Synonyms: (2e)-n-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide;Neratinib(HKI-272);(2E)-N-[4-[[3-chloro-4-(2-pyridinylMethoxy)phenyl]aMino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(diMethylaMino)-2-butenaMide;neratinib;(E)-N-[4-[3-Chloro-4-[(2-pyridinyl)methoxy]anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide;N-(4-(3-Chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide;Unii-jjh94R3pwb;HKI-272; HKI272; HKI 272
CAS: 698387-09-6
MF: C30H29ClN6O3
MW: 557.04
EINECS: 811-237-1
Neratinib developed by US Wyeth company is an irreversible epidermal growth factor receptor(EGFR) inhibitor. It is a multiple target point of small molecule tyrosine kinase inhibitors to HER 2 and HER1 after Lapatinib, and is an irreversible ErbB receptor tyrosine kinase inhibitor. Neratinib could selectively inhibit HER-1 and HER-2 of EGFR family(IC50 was 92 nmol/L and 59 nmol/L, respectively). Clinical research showed that Neratinib exerted significant therapeutic effect on non-small cell lung cancer, colon cancer, and breast cancer.
The phase clinical trial indicated that Neratinib showed good efficacy and tolerance to HER-2 positive patients with advanced breast cancer who had been received or not Trastuzumab treatment.
The phase breast cancer clinical trial was complete in September 2014. The data indicated that the efficacy of Neratinib was better than Roche's Herceptin in treatment of HER-2 positive early breast cancer.
Uses
Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM, respectively.
An oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Antitumor agent
Product Name: Neratinib
Synonyms: (2e)-n-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide;Neratinib(HKI-272);(2E)-N-[4-[[3-chloro-4-(2-pyridinylMethoxy)phenyl]aMino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(diMethylaMino)-2-butenaMide;neratinib;(E)-N-[4-[3-Chloro-4-[(2-pyridinyl)methoxy]anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide;N-(4-(3-Chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide;Unii-jjh94R3pwb;HKI-272; HKI272; HKI 272
CAS: 698387-09-6
MF: C30H29ClN6O3
MW: 557.04
EINECS: 811-237-1
Neratinib developed by US Wyeth company is an irreversible epidermal growth factor receptor(EGFR) inhibitor. It is a multiple target point of small molecule tyrosine kinase inhibitors to HER 2 and HER1 after Lapatinib, and is an irreversible ErbB receptor tyrosine kinase inhibitor. Neratinib could selectively inhibit HER-1 and HER-2 of EGFR family(IC50 was 92 nmol/L and 59 nmol/L, respectively). Clinical research showed that Neratinib exerted significant therapeutic effect on non-small cell lung cancer, colon cancer, and breast cancer.
The phase clinical trial indicated that Neratinib showed good efficacy and tolerance to HER-2 positive patients with advanced breast cancer who had been received or not Trastuzumab treatment.
The phase breast cancer clinical trial was complete in September 2014. The data indicated that the efficacy of Neratinib was better than Roche's Herceptin in treatment of HER-2 positive early breast cancer.
Uses
Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM, respectively.
An oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Antitumor agent
You Might Also Like
Skin Whitening Fish Collagen Powder Proteins Collagen Peptid......
Hardbanding/ Hardfacing Cladding/Cladded Stainless Steel Flu......
Rosewood Furniture Engraving CNC Router (DW1325)
Large Capacity Tree Shredder Ce Approved
OEM Kids Clothes Girls Tropical Sun Dress Baby Cotton Frocks......
Good Price Tenofovir Alafenamide CAS 379270-37-8 with Safe D......
ASTM A681 AISI D2 H13 P20 A2 O1 S7 Round Forged Rolled Tool ......
1, 2-Ethanediol Reagent Glycol Reagent 1, 2-Dihydroxyethane ......
Cl1z -Ajw60c Comlom 600ml PU Cover Stainless Steel Cocktail ......
Machine Room Freight Elevator of Hydraulic Lift
D1835 -9063 Chinese Wholesale Auto Spare Parts Front (4 piec......